Age-Related Reduction in Estrogen Receptor-Mediated Mechanisms of Vascular Relaxation in Female Spontaneously Hypertensive Rats

Hypertension

Volumn 43, Issue 2, 2004, Pages 405-412

  Wynne, Fanisha L ^a   Payne, Jason A ^a   Cain, Ashley E ^a   Reckelhoff, Jane F ^a   Khalil, Raouf A ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; Endothelium; Hormones; Muscle, smooth, vascular

Indexed keywords

CALCIUM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; NITRATE; NITRITE; PHENYLEPHRINE; POTASSIUM CHLORIDE;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; BLOOD PRESSURE; CALCIUM TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; FEMALE; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SMOOTH MUSCLE CONTRACTION; STRESS; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

AGE FACTORS; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM; CULTURE TECHNIQUES; CYCLIC GMP; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HYPERTENSION; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RATS, INBRED SHR; RECEPTORS, ESTROGEN; VASODILATION;

EID: 0842311488     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.0000111833.82664.0c     Document Type: Article

References (48)

1. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996; 10: 615-624.
2. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension. 2000; 35: 480-483.
3. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001; 37: 1199-1208.
4. Thompson J, Khalil RA. Gender differences in the regulation of vascular tone. Clinical Exp Pharmacol Physiol. 2003; 30: 1-15.
5. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen?: from bedside to bench. Circulation. 1995; 92: 5-8.
6. Tolbert T, Oparil S. Cardiovascular effects of estrogen. Am J Hypertens. 2001; 14 (6 Pt 2): 186S-193S.
7. Fortepiani LA, Zhang H, Racusen L, Roberts LJ 2nd, Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension. 2003; 41: 640-645.
8. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342: 133-136.
9. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, and Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.
10. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001; 103: 638-642.
11. Enstrom I, Lidfeldt J, Lindholm LH, Nerbrand C, Pennert K, Samsioe G. Does blood pressure differ between users and non-users of hormone replacement therapy?: the Women’s Health In the Lund Area (WHILA) Study. Blood Press. 2002; 11: 240-243.
12. Grimes DA, Lobo RA. Perspectives on the Women’s Health Initiative trial of hormone replacement therapy. Obstet Gynecol. 2002; 100: 1344-1353.
13. Mills PJ, Farag NH, Matthews S, Nelesen RA, Berry CC, Dimsdale JE. Hormone replacement therapy does not affect 24-h ambulatory blood pressure in healthy non-smoking postmenopausal women. Blood Press Monit. 2003; 8: 57-61.
14. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors α and β: prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000; 101: 1792-1798.
15. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002; 90: 3F-6F.
16. Scobie GA, Macpherson S, Millar MR, Groome NP, Romana PG, Saunders PT. Human oestrogen receptors: differential expression of ER α and β and the identification of ER β variants. Steroids. 2002; 67: 985-992.
17. Dan P, Cheung JC, Scriven DR, Moore ED. Epitope-dependent localization of estrogen receptor-α, but not -β, in en face arterial endothelium. Am J Physiol. 2003; 284: H1295-H1306.
18. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-estradiol in vitro. Br J Pharmacol. 1991; 104: 1033-1037.
19. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 1992; 263: H271-H275.
20. 2+ entry mechanisms of coronary vasoconstriction. Arterioscel Thromb Vasc Biol. 1999; 19: 1034-1040.
21. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84: 9265-9269.
22. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J. 1989; 3: 2007-2018.
23. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol. 1999; 31: 5-14.
24. Gruetter CA, Gruetter DY, Lyon JE, Kadowitz PJ, Ignarro LJ. Relationship between cyclic guanosine 3′, 5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther. 1981; 219: 181-186.
25. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol. 1985; 25: 171-191.
26. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, Shaul PW. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997; 81: 355-362.
27. 2+ and ecNOS activity. Am J Physiol. 1999; 276: H961-H969.
28. Tan E, Gurjar MV, Sharma RV, Bhalla RC. Estrogen receptor-α gene transfer into bovine aortic endothelial cells induces eNOS gene expression and inhibits cell migration. Cardiovasc Res. 1999; 43: 788-797.
29. Geary GG, Krause DN, and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol. 2000; 279: H511-H519.
30. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000; 87: 677-682.
31. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR. Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol. 2001; 280: H1699-H1705.
32. Khalil RA, van Breemen C. Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation? J Pharmacol Exp Ther. 1988; 244: 537-542.
33. i during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 1999; 291: 44-52.
34. i in vascular smooth muscle cells of female rat. Am J Physiol. 2000; 278: C834-C844.
35. Walker LA, Buscemi-Bergin M, Gellai M. Renal hemodynamics in conscious rats: effects of anesthesia, surgery, and recovery. Am J Physiol. 1983; 245: F67-F74.
36. Hussain AS, Marks GS, Brien JF, Nakatsu K. The soluble guanylyl cyclase inhibitor 1H-[1, 2, 4]oxadiazolo[4, 3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Can J Physiol Pharmacol. 1997; 75: 1034-1037.
37. Olson LJ, Knych ET Jr., Herzig TC, and Drewett JG. Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation. Hypertension. 1997; 29: 254-261.
38. Giardina JB, Green GM, Rinewalt AN, Granger JP, Khalil RA. Role of endothelin B receptors in enhancing endothelium-dependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension. 2001; 37: 516-523.
39. Payne JA, Reckelhoff JF, Khalil RA. Role of oxidative stress in age-related reduction of NO-cGMP mediated vascular relaxation in SHR. Am J Physiol. 2003; 285: R542-R551.
40. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol. 2001; 280: C34-C45.
41. Lim KB, Ng CY, Ong CK, Ong CS, Tran E, Nguyen TT, Chan GM, Huynh H. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat. 2001; 68: 127-138.
42. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Cano A. Inhibition of low-density lipoprotein oxidation by the pure antiestrogens ICI 182780 and EM-652 (SCH 57068). Menopause. 2002; 9: 430-435.
43. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999; 103: 401-406.
44. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001; 276: 3459-3467.
45. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000; 97: 5930-5935.
46. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol. 1994; 266: C975-C980.
47. 2+ entry inhibition. J Cereb Blood Flow Metab. 2001; 21: 422-429.
48. Ca channels through a cGMP-dependent mechanism. Circ Res 1995; 77: 936-942.